MMP-9-IN-1|cas:502887-71-0|西域试剂

MMP-9-IN-1,99.71%

产品编号：Bellancom-135232| CAS NO：502887-71-0| 分子式：C₁₆H₁₇F₂N₃O₃S| 分子量：369.39

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-135232	￥3500.00	杭州北京（现货）
Bellancom-135232	￥5500.00	杭州北京（现货）
Bellancom-135232	￥0.00	杭州北京（现货）
Bellancom-135232	￥0.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

MMP-9-IN-1

产品介绍

MMP-9-IN-1 是一种特异性的基质金属蛋白酶-9 (MMP-9) 抑制剂，选择性靶向 MMP-9 的血红素 (PEX) 域，但不作用于其他 MMP。

生物活性

MMP-9-IN-1 is a specific matrix metalloproteinase-9 (MMP-9) inhibitor, which selectively target the hemopexin (PEX) domain of MMP-9, but not other MMPs.

体外研究

MMP-9-IN-1 (compound 2; 100 μM; 14 hours) does not cause notable cytotoxicity.
MMP-9-IN-1 (compound 2; 10 μM) significantly inhibits cell proliferation of HT-1080 and MDA-MB-435 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay

Cell Line:	COS-1 monkey epithelial cell lines
Concentration:	100 μM
Incubation Time:	24 hours
Result:	Treatment did not cause notable cytotoxicity.

Cell Proliferation Assay

Cell Line:	HT-1080 and MDA-MB-435 cancer cells expressing endogenous MMP-9
Concentration:	10 μM
Incubation Time:	9 days
Result:	Significant inhibition of cell proliferation.

体内研究
(In Vivo)

MMP-9-IN-1 (compound 2; 20 mg/kg; intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks) results in a profound delay in tumor growth in NCR-Nu mice bearing MDA-MB-435/GFP tumor.
MMP-9-IN-1 inhibits cancer cell metastasis in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	4-5 week-old female NCR-Nu mice bearing MDA-MB-435/GFP tumor
Dosage:	20 mg/kg
Administration:	Intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks,
Result:	Resulted in a profound delay in tumor growth. Inhibited cancer cell metastasis.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	4-5 week-old female NCR-Nu mice bearing MDA-MB-435/GFP tumor
Dosage:	20 mg/kg
Administration:	Intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks,
Result:	Resulted in a profound delay in tumor growth. Inhibited cancer cell metastasis.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	4-5 week-old female NCR-Nu mice bearing MDA-MB-435/GFP tumor
Dosage:	20 mg/kg
Administration:	Intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks,
Result:	Resulted in a profound delay in tumor growth. Inhibited cancer cell metastasis.

性状

Solid

溶解性数据

In Vitro:

DMSO : 66.67 mg/mL (180.49 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7072 mL	13.5358 mL	27.0717 mL
5 mM	0.5414 mL	2.7072 mL	5.4143 mL
10 mM	0.2707 mL	1.3536 mL	2.7072 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 50% PBS
Solubility: 5 mg/mL (13.54 mM); Suspended solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.63 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.63 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。